What are the potential risks and benefits of this intermittent abiraterone approach compared to continuous...
Here is some information on the potential risks and benefits of intermittent vs continuous abiraterone treatment for prostate cancer, based on guidelines from trusted medical sources:
According to the NCCN Guidelines for Prostate Cancer, intermittent androgen deprivation therapy (ADT) approaches like intermittent abiraterone may reduce side effects compared to continuous ADT. However, they note that the long-term efficacy of intermittent ADT compared to continuous ADT remains unclear based on current evidence. Close monitoring of PSA and testosterone levels is recommended during off-treatment periods.
The American Urological Association guidelines state that intermittent ADT may be offered as an alternative to continuous ADT for patients with non-metastatic or metastatic prostate cancer. Potential benefits include decreased side effects and improved quality of life during off-treatment intervals. However, they emphasize there is no clear evidence that survival with intermittent ADT is equivalent to continuous ADT.
To monitor for any changes in your cancer during the abiraterone treatment breaks, the NCCN recommends:
- Regular PSA testing every 3-6 months
- Periodic imaging with CT, MRI or bone scans as clinically indicated based on symptoms and PSA trends
- Tracking testosterone levels to ensure adequate suppression during treatment periods
It's important to have close follow-up with your oncologist during intermittent therapy to catch any signs of disease progression early. Always consult with your doctor about the best treatment approach and monitoring plan for your individual situation. They can provide personalized guidance on balancing the risks and benefits of intermittent vs continuous therapy for your prostate cancer.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Prostate Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Question asked:
What are the potential risks and benefits of this intermittent abiraterone approach compared to continuous treatment? How will we monitor for any changes in your cancer during the treatment breaks?
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Prostate Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Prostate Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Prostate Cancer
- I've finished radiation therapy while continuing on ADT and Abiraterone. How do I know how I'm doing? My...
- Is cologuard a trusted diagnostic compared to colonoscopy? How about false positive/negative
- What is the risk of getting a second cancer after Prostate Cancer treatment
- What is the risk of infection after Prostate Cancer surgery
- What should I know about PRS risk scoring methodologies
- Can you walk me through what the treatment schedule and monitoring plan would look like with the intermittent...
- Can exercise reduce the risk of Prostate Cancer recurrence
- What should I know about blood clot risk during Prostate Cancer treatment